References
- Braun‐Falco O., Plewing G., Wolff H. H. Dermatology. Springer‐Verlag, Berlin and Heidelberg 2000, 4th ed
- Ortonne J. P. Vitiligo and other disorders of hypopigmentation. Dermatology, J. B Bolognia, J. L Jorizzo, R. P Rapini. Elsevier Science, Spain 2003; 947–54
- Mosher D. B., Fitzpatrick T. B., Ortonne J. P. Hypomelanoses and hypermelanoses. Dermatology in general medicine, T. B Fitzpatrick, A. Z Eisen, K Wolf, I. M Freedberg. Mc Graw‐Hill, New York 1999; 954–60, 5th ed
- Kovacs S. O. Vitiligo. J Am Acad Dermatol 1998; 38: 647–66
- Kostovic K., Pasic A. New treatment modalities for vitiligo: Focus on topical immunomodulators. Drugs 2005; 65: 447–59
- Silverberg N. B., Lin P., Travis L., Farley‐Li J., Mancini A. J., Wagner A. M., et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: A review of 57 cases. J Am Acad Dermatol 2004; 51: 760–6
- Njoo M. D., Bossuyt P. M., Westerhof W. Management of vitiligo. Results of a questionnaire among dermatologists in The Netherlands. Int J Dermatol 1999; 38: 866–72
- Sharma N., Koranne R. V., Singh R. K. Psychiatric morbidity in psoriasis and vitiligo: A comparative study. J Dermatol 2001; 28: 419–23
- Mattoo S. K., Handa S., Kaur I., Gupta N., Malhotra R. Psychiatric morbidity in vitiligo and psoriasis: A comparative study from India. J Dermatol 2001; 28: 424–32
- Gupta A. K., Chow M. Pimecrolimus: A review. J Eur Acad Dermatol Venereol 2003; 17: 493–503
- Paul C., Graeber M., Stuetz A. Ascomycins: Promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs 2000; 9: 69–77
- Grassberger M., Baumruker T., Enz A., Hiestand P., Hultsch T., Kalthoff F., et al. A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Dermatol 1999; 141: 263–73
- Grimes P. E., Morris R., Avaniss‐Aghajani E., Soriano T., Meraz M., Metzger A. Topical tacrolimus therapy for vitiligo: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51: 52–61
- Grimes P. E. New insights and new therapies in vitiligo. JAMA 2005; 293: 730–5
- Handa S., Pandhi R., Kaur I. Vitiligo: A retrospective comparative analysis of treatment modalities in 500 patients. J Dermatol 2001; 28: 461–6
- Njoo M. D., Bos J. D., Westerhof W. Treatment of generalized vitiligo in children with narrow‐band (TL‐01) UVB radiation therapy. J Am Acad Dermatol 2000; 42: 245–53
- Tjioe M., Vissers W. H., Gerritsen M. J. Topical macrolide immunomodulators: A role in the treatment of vitiligo?. Am J Clin Dermatol 2006; 7: 7–12
- Gribetz C., Ling M., Lebwohl M., Pariser D., Draelos Z., Gottlieb A. B., et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double‐blind randomized study. J Am Acad Dermatol 2004; 51: 731–8
- Kreuter A., Gambichler T., Breuckmann F., Pawlak F. M., Stucker M., Bader A., et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51: 407–10
- Queille‐Roussel C., Graeber M., Thurston M., Lachapelle J. M., Decroix J., de Cuyper C., et al. SDZ ASM 981 is the first non‐steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000; 42: 349–50
- Smith D. A., Tofte S. J., Hanifin J. M. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205: 301–3
- Grimes P. E., Soriano T., Dytoc M. T. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789–91
- Mayoral F. A., Gonzales C., Shah N. S., Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: A case report. Dermatology 2003; 207: 322–3
- Lepe V., Moncada B., Castanedo‐Cazares J. P., Torres‐Alvarez M. B., Ortiz C. A., Torres‐Rubalcava A. B. A double‐blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581–5
- Coskun B., Saral Y., Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88–91